Ma­gen­ta sets up Di­anthus merg­er in quick, three-month about-face af­ter end­ing tri­al due to pa­tient death

Ma­gen­ta Ther­a­peu­tics will give its spot on Nas­daq to pri­vate­ly-held Di­anthus Ther­a­peu­tics af­ter a pa­tient death spurred an end to Ma­gen­ta’s clin­i­cal work and an ex­it for most of the com­pa­ny’s em­ploy­ees.

Af­ter the pa­tient death was re­port­ed in late-Jan­u­ary, Ma­gen­ta fol­lowed up a week lat­er say­ing it would go through a re­view of al­ter­na­tives, in­clud­ing a merg­er or oth­er trans­ac­tion. The com­pa­ny had set out to de­vel­op an al­ter­na­tive pre-con­di­tion­ing reg­i­men for stem cell trans­plan­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER